# Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Combination Therapy in Patients With Hypertension Not Controlled With Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy

> **NCT01838850** · PHASE3 · COMPLETED · sponsor: **Daiichi Sankyo Korea Co., Ltd., a Daiichi Sankyo Company** · enrollment: 344 (actual)

## Conditions studied

- Essential Hypertension

## Interventions

- **DRUG:** CS8635 20/5/12.5mg and placebo
- **DRUG:** Olmetec® Plus 20/12.5mg and placebo

## Key facts

- **NCT ID:** NCT01838850
- **Lead sponsor:** Daiichi Sankyo Korea Co., Ltd., a Daiichi Sankyo Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04
- **Primary completion:** 2014-08
- **Final completion:** 2014-08
- **Target enrollment:** 344 (ACTUAL)
- **Last updated:** 2018-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01838850

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01838850, "Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Combination Therapy in Patients With Hypertension Not Controlled With Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT01838850. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*